Innovative Gas Sensors Expand SSB's PAT Portfolio
Sartorius Stedim Biotech (SSB), a leading international supplier of pharmaceutical and biotech equipment, has entered into a global sales partnership with BlueSens, the German experts in gasometric engineering. BlueSens is a highly specialized provider of sensor technology, which is used by the biopharmaceutical industry for inline measurement of gases in microbial fermentation and cell cultivation processes. The co-operation agreement between SSB and BlueSens provides that, alongside BlueSens, SSB will assume global marketing and distribution of its partner company’s oxygen and carbon dioxide sensors, and sell these as private label products under SSB’s brand name BioPAT Xgas.
During the past years, SSB has continuously expanded its process analytics portfolio in the area of sensor technology to measure critical process parameters, such as pH and dissolved oxygen, temperature, glucose, lactate and biomass, non-invasively and in real time. The new oxygen and carbon dioxide sensors are further important additions to SSB’s range of analytical products. BioPAT Xgas enables precise, reproducible information to be obtained about the progress of fermentation, without having to take samples and analyze them off-line in a laboratory.
Stefan Schlack, Senior Vice President of Marketing at SSB, said: "These sensors make our bioreactors even more intelligent. They analyse metabolic processes in real time during cultivation and help our customers better understand their processes. Used in combination with our software, these sensors are powerful tools for optimizing biopharmaceutical production processes and accelerating development."
Dr Holger Müller, Sales and Marketing Manager at BlueSens, stated: “In fermentation, SSB is among the leading suppliers worldwide and has a strong, global sales network. We would like to leverage these advantages to reach considerably more customers. I am looking forward to our partnership.“
BioPAT Xgas will be sold as an equipment package that includes SSB’s single-use and reusable bioreactors. Ready to use right out of the box, the sensors are completely integrated into SSB’s BioPAT DCU control units and SCADA software, called BioPAT MFCS.
In conjunction with Sartorius software, BioPAT Xgas analyses critical process variables, such as oxygen uptake rate (OUR), carbon dioxide production rate (CPR) or respiratory quotient (RQ).
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.